N-acetylcysteine and NMDA Antagonist Interactions

• Status: Completed
• Trial end date: 2011-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study tests the hypothesis that extrasynaptic mechanisms are critically linked with cognitive effects of NMDA antagonism as evidenced by event-related potentials (ERPs) in healthy humans.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Yale University
• Treatments: Acetylcysteine; Ketamine; N-monoacetylcystine

Criteria

Inclusion Criteria:

• Ages of 21-45 years from all ethnic backgrounds.

• Male or female.

• Written informed consent.

Exclusion criteria

• DSM-IV diagnosis for a psychotic, depressive or anxiety disorder.

• A history of significant medical/neurological disease such as cardiac, thyroid, renal, hepatic abnormality, seizure disorder. Unstable medical condition based on EKG, vital signs, physical examination and laboratory work-up (CBC with differential, SMA-7, LFTs, TFTs, UA, Utox, Urine pregnancy test) .

• History of severe allergies or multiple adverse drug reactions.

• Any medication that in the opinion of the PI could interfere with either the safety of the study and/or the outcome measures.

• Any other conditions which in the opinion of the investigator would preclude participation in the study.

• History of major psychiatric disorder in first degree relatives.

• Current substance abuse/dependency determined by urine toxicology.

• Current treatment with medications with psychotropic effects.

• Treatment with benzodiazepines within one week prior to testing.

• Current pregnancy, unsatisfactory birth control method report for females.

• Education < 10th grade.

• IQ < 70, MR as determined by Wechsler Abbreviated Scale of Intelligence.

• Non-English speaking.